Adamis Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103
October 9, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Margaret Schwartz, Esq. |
Re: | Adamis Pharmaceuticals Corporation | |||
Registration Statement on Form S-3 (No. 333-249331) | ||||
Filed on October 5, 2020 | ||||
Acceleration Request | ||||
Requested Date: | October 14, 2020 | |||
Requested Time: | 4:00 P.M. Eastern Time |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Adamis Pharmaceuticals Corporation (the "Company") hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-249331) to become effective on Wednesday, October 14, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request or the Registration Statement, please call Kevin Kelso of Weintraub Tobin, the Company’s counsel, at (916) 558-6110.
Very truly yours, | |||
Adamis Pharmaceuticals Corporation | |||
By: | /s/ Robert O. Hopkins | ||
Robert O. Hopkins | |||
Chief Financial Officer |